Market Overview:
The global gene therapy on cardiovascular disease market is expected to grow at a CAGR of 16.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of cardiovascular diseases, technological advancements in gene therapy, and rising investments by key players in the field of gene therapy. Based on type, the global gene therapy on cardiovascular disease market is segmented into viral gene therapy and non-viral gene therapy. Non-viral Gene Therapy held a larger share of the market in 2017 and is expected to grow at a higher CAGR during the forecast period owing to its advantages over viral vectors such as low immunogenicity, easy production process, and lack of pathogenicity. By application, heart disease accounted for majority share of the global market in 2017; however, vascular diseases are expected to witness highest growth rate during the forecast period owing to increasing incidence rates globally.
Product Definition:
Gene therapy is the use of genes to treat or prevent disease. It involves taking cells from a person's body, modifying them in a lab so they produce a protein that fights the disease, and putting them back into the person's body.
The promise of gene therapy is that it could one day be used to cure many diseases, including heart disease. Gene therapy has already been used to successfully treat some forms of blindness and cancer. The importance of gene therapy on cardiovascular disease is still being studied, but early results suggest it may be an effective treatment for heart failure and other forms of cardiovascular disease.
Viral Gene Therapy:
The global viral gene therapy market is expected to witness significant growth over the forecast period owing to its usage in treating genetic diseases, cancer and other chronic conditions. Viral gene therapy has been used as a treatment for various life-threatening diseases such as HIV, Hepatitis C & B and Leukemia. The major advantage of viral gene therapy is that it works directly at the cellular level without targeting the immune system which makes it an effective treatment for curing several chronic disorders.
Non-Viral Gene Therapy:
Non-viral gene therapy is a new treatment for genetic diseases that do not respond to conventional therapies. It's majorly used for the treatment of serious cardiovascular diseases such as arrhythmias, heart failure and congenital long QT syndrome among others. The therapy works by delivering a functional copy of the gene into cells where the original version of this gene was not functioning properly.
Application Insights:
The heart disease segment dominated the market in 2017 and is expected to witness lucrative growth during the forecast period owing to increasing prevalence of cardiac disorders. According to a study published by NCBI, it was estimated that around 647 million people across the globe have some form of cardiovascular diseases (CVDs). Furthermore, another study states that out of all CVDs, around 562 million were reported globally in 2015. Thus, it can be concluded that there is a huge potential demand for gene therapy on CVDs which will drive market growth over the forecast period.
Vascular diseases are also one of the major application areas where gene therapy has been used with considerable success and this segment is expected to grow at a significant rate during future years due largely non-inherited genetic mutations associated with vascular diseases such as Marfan syndrome & Loeys-Dietz syndrome which cause death or disability in young adulthood.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to various factors such as favorable government initiatives, high prevalence of cardiovascular diseases, and availability of effective treatment methods in this region. For instance, according to data published by the National Center for Biotechnology Information (NCBI), around 29 million people suffer from heart failure in U.S., with a projected increase to more than 6 million by 2025 if current trends continue.
Asia Pacific is expected to witness lucrative growth over the coming years owing to rising disposable income and improving healthcare infrastructure especially in emerging countries such as China and India. In addition, an increasing number of clinical trials being conducted across Asia Pacific are expected drive regional market growth during the forecast period such as ongoing studies on gene therapy for cancer treatment or prevention & management of HIV/AIDS infection among others).
Growth Factors:
- Increasing prevalence of cardiovascular diseases (CVDs) across the globe
- Growing geriatric population susceptible to CVDs
- Rising awareness about gene therapy as a treatment for CVDs
- Technological advancements in gene therapy treatments for CVDs
- increasing investment by pharmaceutical and biotechnology companies in research and development of novel gene therapies for the treatment of CVDs
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Therapy On Cardiovascular Disease Market Research Report
By Type
Viral Gene Therapy, Non-Viral Gene Therapy
By Application
Heart Disease, Vascular Disease
By Companies
Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
201
Number of Tables & Figures
141
Customization Available
Yes, the report can be customized as per your need.
Global Gene Therapy On Cardiovascular Disease Market Report Segments:
The global Gene Therapy On Cardiovascular Disease market is segmented on the basis of:
Types
Viral Gene Therapy, Non-Viral Gene Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Heart Disease, Vascular Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Highlights of The Gene Therapy On Cardiovascular Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Viral Gene Therapy
- Non-Viral Gene Therapy
- By Application:
- Heart Disease
- Vascular Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Therapy On Cardiovascular Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gene therapy is a treatment that uses genetic material to correct or prevent disease. Cardiovascular disease (CVD) is a broad term that refers to diseases of the heart and blood vessels. Gene therapy can be used to treat CVD by correcting or preventing the development of atherosclerosis, heart failure, and stroke.
Some of the key players operating in the gene therapy on cardiovascular disease market are Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute.
The gene therapy on cardiovascular disease market is expected to register a CAGR of 16.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gene Therapy On Cardiovascular Disease Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gene Therapy On Cardiovascular Disease Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gene Therapy On Cardiovascular Disease Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gene Therapy On Cardiovascular Disease Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gene Therapy On Cardiovascular Disease Market Size & Forecast, 2018-2028
4.5.1 Gene Therapy On Cardiovascular Disease Market Size and Y-o-Y Growth
4.5.2 Gene Therapy On Cardiovascular Disease Market Absolute $ Opportunity
Chapter 5 Global Gene Therapy On Cardiovascular Disease Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
5.2.1 Viral Gene Therapy
5.2.2 Non-Viral Gene Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gene Therapy On Cardiovascular Disease Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
6.2.1 Heart Disease
6.2.2 Vascular Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gene Therapy On Cardiovascular Disease Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gene Therapy On Cardiovascular Disease Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gene Therapy On Cardiovascular Disease Analysis and Forecast
9.1 Introduction
9.2 North America Gene Therapy On Cardiovascular Disease Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
9.6.1 Viral Gene Therapy
9.6.2 Non-Viral Gene Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
9.10.1 Heart Disease
9.10.2 Vascular Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gene Therapy On Cardiovascular Disease Analysis and Forecast
10.1 Introduction
10.2 Europe Gene Therapy On Cardiovascular Disease Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
10.6.1 Viral Gene Therapy
10.6.2 Non-Viral Gene Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
10.10.1 Heart Disease
10.10.2 Vascular Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gene Therapy On Cardiovascular Disease Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gene Therapy On Cardiovascular Disease Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
11.6.1 Viral Gene Therapy
11.6.2 Non-Viral Gene Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
11.10.1 Heart Disease
11.10.2 Vascular Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gene Therapy On Cardiovascular Disease Analysis and Forecast
12.1 Introduction
12.2 Latin America Gene Therapy On Cardiovascular Disease Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
12.6.1 Viral Gene Therapy
12.6.2 Non-Viral Gene Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
12.10.1 Heart Disease
12.10.2 Vascular Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gene Therapy On Cardiovascular Disease Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gene Therapy On Cardiovascular Disease Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gene Therapy On Cardiovascular Disease Market Size Forecast by Type
13.6.1 Viral Gene Therapy
13.6.2 Non-Viral Gene Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gene Therapy On Cardiovascular Disease Market Size Forecast by Applications
13.10.1 Heart Disease
13.10.2 Vascular Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gene Therapy On Cardiovascular Disease Market: Competitive Dashboard
14.2 Global Gene Therapy On Cardiovascular Disease Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Novartis
14.3.3 Gilead Sciences
14.3.4 Sarepta Therapeutics
14.3.5 Alnylam Pharmaceuticals
14.3.6 Amgen
14.3.7 Spark Therapeutics
14.3.8 Akcea Therapeutics
14.3.9 bluebird bio
14.3.10 Sunway Biotech
14.3.11 SIBIONO
14.3.12 AnGes
14.3.13 Orchard Therapeutics
14.3.14 Human Stem Cells Institute
